Différenciation des cellules hématopoïétiques : intervention des cytokines et expression des marqueurs membranaires, Rev. Fr. Allergol. Immunol. Clin, vol.36, pp.859-878, 1996. ,
, Annu. Rev. Immunol, vol.24, pp.287-320, 2006.
c-Myb is required for plasma cell migration to bone marrow after immunization or infection, J. Exp. Med, vol.212, pp.1001-1009, 2015. ,
Structure and Function of Immunoglobulins, J. Allergy Clin. Immunol, vol.125, pp.41-52, 2010. ,
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-548, 2014. ,
Prevalence of monoclonal gammopathy of undetermined significance, N. Engl. J. Med, vol.354, pp.1362-1369, 2006. ,
Monoclonal gammopathy of undetermined significance, Br. J. Haematol, vol.134, pp.573-589, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00945713
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma, N. Engl. J. Med, vol.356, pp.2582-2590, 2007. ,
Cancer statistics, 2019. CA, Cancer J. Clin, vol.69, pp.7-34, 2019. ,
, Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012: étude à partir des registres des cancers du réseau Francim, 2013.
Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clin. Proc, vol.78, pp.21-33, 2003. ,
Multiple myeloma: A review of the epidemiologic literature, Int. J. Cancer, vol.120, pp.40-61, 2007. ,
Cytogénétique et génétique moléculaire du myélome multiple, Rev. Francoph. Lab, pp.50-57, 2019. ,
Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management, Am. J. Hematol, vol.93, pp.1091-1110, 2018. ,
Pathogenesis beyond the cancer clone(s) in multiple myeloma, Blood, vol.125, pp.3049-3058, 2015. ,
Gammapathie monoclonale de signification indéterminée, myélome multiple et ostéoporose, Rev. Rhum, vol.77, pp.144-148, 2010. ,
os du myélome multiple : physiopathologie, Rev. Rhum. Monogr, vol.84, pp.181-186, 2017. ,
, The International Myeloma Working Group*. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br. J. Haematol, vol.121, pp.749-757, 2003.
Multiple myeloma: clinical features and indications for therapy, Best Pract. Res. Clin. Haematol, vol.18, pp.553-568, 2005. ,
Multiple myeloma/hypercalcemia, Arthritis Res. Ther, vol.9, issue.1, p.4, 2007. ,
, Hyperviscosity Syndrome in Plasma Cell Dyscrasias. Semin. Thromb. Hemost, vol.29, pp.467-472, 2003.
Neurological aspects of multiple myeloma and related disorders, Best Pract. Res. Clin. Haematol, vol.18, pp.673-688, 2005. ,
Clinical course and prognosis of non-secretory multiple myeloma, Eur. J. Haematol, vol.95, pp.57-64, 2015. ,
Cytogenetics in the management of multiple myeloma: an update by the Groupe francophone de cytogénétique hématologique (GFCH), Ann. Biol. Clin, pp.588-595, 20169. ,
Molecular pathogenesis of multiple myeloma: basic and clinical updates, Int. J. Hematol, vol.97, pp.313-323, 2013. ,
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, J. Clin. Oncol, vol.33, pp.2863-2869, 2015. ,
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel, J. Hematol. Oncol.J Hematol Oncol, vol.11, 2018. ,
, Médecine Interne, vol.36, pp.89-97, 2015.
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias, Leukemia, 2018. ,
New advances in the diagnosis and treatment of POEMS syndrome, Br. J. Haematol, vol.161, pp.303-315, 2013. ,
, the International Myeloma Working Group et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group, vol.27, pp.780-791, 2013.
Plasma cell morphology in multiple myeloma and related disorders, Morphologie, vol.99, pp.38-62, 2015. ,
Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration, Br. J. Haematol, vol.133, pp.530-532, 2006. ,
Use of multiparameter flow cytometry in multiple myeloma and other plasma cell neoplasms, Belg. J. Hematol, vol.6, pp.46-53, 20150501. ,
IFM (Intergroupe francophone du myélome) recommendations for uniform interpretation of serum and urine protein electrophoresis in multiple myeloma diagnosis and follow-up, Ann. Biol. Clin, pp.429-441 ,
International Myeloma Working Group recommendations for global myeloma care, Leukemia, vol.28, pp.981-992, 2014. ,
Urinary investigations in the diagnosis and monitoring of monoclonal gammopathies in daily practice, Ann. Biol. Clin, pp.147-152 ,
Urinary protein electrophoresis, which analysis to select? A simplified interpretation, Ann. Biol. Clin, pp.667-678, 201311. ,
READY FOR A NEW DEFINITION?, Mediterr. J. Hematol. Infect. Dis, vol.9, p.2017053, 2017. ,
, International Myeloma Working Group27 et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders, Leukemia, vol.23, pp.215-224, 2009.
,
, Ann. Biol. Clin, vol.66, pp.427-431, 2008.
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, vol.17, pp.328-346, 2016. ,
Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014, Blood Cancer J, vol.6, pp.409-409, 2016. ,
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement, Bone Marrow Transplant, vol.54, pp.353-367, 2019. ,
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, vol.117, pp.4691-4695, 2011. ,
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience, Expert Rev. Clin. Immunol, vol.14, pp.197-206, 2018. ,
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma, Blood, vol.134, pp.668-677, 2019. ,
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment, Clin. Pharmacokinet, vol.56, pp.915-924, 2017. ,
, Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development: Tutorial on Monoclonal Antibody Pharmacokinetics, vol.11, pp.540-552, 2018.
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma, Adv. Ther, vol.35, pp.1859-1872, 2018. ,
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma, Drugs, vol.76, pp.853-867, 2016. ,
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma, Drugs, vol.77, pp.2013-2024, 2017. ,
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma, Blood, vol.127, pp.681-695, 2016. ,
Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay, Clin. Biochem, vol.49, pp.1202-1204, 2016. ,
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA), Clin. Chem. Lab. Med. CCLM, vol.54, 2016. ,
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection, Haematologica, vol.102, pp.368-370, 2017. ,
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma, Blood, vol.128, pp.959-970, 2016. ,
Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma, Ann. Biol. Clin, vol.75, pp.351-355, 2017. ,
Daratumumab: Therapeutic asset, biological trap! Transfus, Clin. Biol, vol.25, pp.2-7, 2018. ,
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference, Clin. Chem. Lab. Med. CCLM, vol.54, 2016. ,
Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab, Blood, vol.128, pp.2063-2063, 2016. ,
Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay, J. Appl. Lab. Med, vol.3, pp.857-863, 2019. ,
Identification of Friend or Foe: The Laboratory Challenge of Differentiating M-Proteins from Monoclonal Antibody Therapies, J. Appl. Lab. Med. AACC Publ, vol.1, pp.421-431, 2017. ,
,
, Je jure, en présence des Maîtres de la Faculté
, D'honorer ceux qui m'ont instruit dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement
, intérêt de la santé publique, ma profession avec conscience et de respecter non seulement la législation en vigueur, mais aussi les règles de l'honneur
, De ne jamais oublier ma responsabilité et mes devoirs envers le malade et sa dignité humaine, de respecter le secret professionnel
, En aucun cas, je ne consentirai à utiliser mes connaissances et mon état pour corrompre les moeurs et favoriser des actes criminels
, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses
, Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque